BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27033920)

  • 1. Evaluation of apoptosis-associated protein (Bcl-2, Bax, cleaved caspase-3 and p53) expression in canine mammary tumors: An immunohistochemical and prognostic study.
    Dolka I; Król M; Sapierzyński R
    Res Vet Sci; 2016 Apr; 105():124-33. PubMed ID: 27033920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between receptors for insulin-like growth factor- I, steroid hormones and apoptosis-associated proteins in canine mammary tumors.
    Dolka I; Motyl T; Malicka R; Sapierzyński E; Fabisiak M
    Pol J Vet Sci; 2011; 14(2):245-51. PubMed ID: 21721409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors.
    Lee CH; Kim WH; Lim JH; Kang MS; Kim DY; Kweon OK
    J Vet Sci; 2004 Mar; 5(1):63-9. PubMed ID: 15028887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin and related proteins in canine mammary tumors: immunohistochemical expression.
    Bongiovanni L; Romanucci M; Malatesta D; D'Andrea A; Ciccarelli A; Della Salda L
    Vet Pathol; 2015 Mar; 52(2):269-75. PubMed ID: 24686389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression frequency of c-kit isoforms and its prognostic potential in canine mammary tumours.
    Chen YC; Liao JW; Chang SC; Hsu WL
    Vet Comp Oncol; 2020 Sep; 18(3):303-314. PubMed ID: 31652393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
    Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
    Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 and PCNA Expression in Canine Mammary Tumors and Adjacent Nonneoplastic Mammary Glands: Prognostic Impact by a Multivariate Survival Analysis.
    Carvalho MI; Pires I; Prada J; Lobo L; Queiroga FL
    Vet Pathol; 2016 Nov; 53(6):1138-1146. PubMed ID: 27162119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and prognostic value of c-met in canine mammary tumours.
    Chen YC; Chen YY; Liao JW; Chang SC
    Vet Comp Oncol; 2018 Dec; 16(4):670-676. PubMed ID: 30129270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A canine model of familial mammary gland neoplasia.
    Schafer KA; Kelly G; Schrader R; Griffith WC; Muggenburg BA; Tierney LA; Lechner JF; Janovitz EB; Hahn FF
    Vet Pathol; 1998 May; 35(3):168-77. PubMed ID: 9598580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of FOXP3 expression in canine mammary gland tumours.
    Oh SY; Ryu HH; Yoo DY; Hwang IK; Kweon OK; Kim WH
    Vet Comp Oncol; 2014 Mar; 12(1):20-8. PubMed ID: 22541038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
    Gama A; Alves A; Schmitt F
    Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic status of p53 gene mutation in canine mammary carcinoma.
    Wakui S; Muto T; Yokoo K; Yokoo R; Takahashi H; Masaoka T; Hano H; Furusato M
    Anticancer Res; 2001; 21(1B):611-6. PubMed ID: 11299814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral FoxP3 expression is associated with angiogenesis and prognosis in malignant canine mammary tumors.
    Carvalho MI; Pires I; Prada J; Gregório H; Lobo L; Queiroga FL
    Vet Immunol Immunopathol; 2016 Oct; 178():1-9. PubMed ID: 27496736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors.
    Lee CH; Kweon OK
    J Vet Sci; 2002 Dec; 3(4):321-5. PubMed ID: 12819382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors.
    Moschetta MG; Maschio LB; Jardim-Perassi BV; Gelaleti GB; Lopes JR; Leonel C; Gonçalves Ndo N; Ferreira LC; Martins GR; Borin TF; Zuccari DA
    Oncol Rep; 2015 May; 33(5):2345-53. PubMed ID: 25779537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study.
    Santos A; Lopes C; Frias C; Amorim I; Vicente C; Gärtner F; Matos Ad
    Vet J; 2011 Dec; 190(3):396-402. PubMed ID: 21269852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of autophagy-related protein Beclin-1 in malignant canine mammary tumors.
    Liu JL; Chang KC; Lo CC; Chu PY; Liu CH
    BMC Vet Res; 2013 Apr; 9():75. PubMed ID: 23578251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of spontaneously occurring canine mammary tumours: Insight into gene networks and pathways linked to cancer pathogenesis.
    Hussain S; Saxena S; Shrivastava S; Mohanty AK; Kumar S; Singh RJ; Kumar A; Wani SA; Gandham RK; Kumar N; Sharma AK; Tiwari AK; Singh RK
    PLoS One; 2018; 13(12):e0208656. PubMed ID: 30517191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical and molecular analysis of caveolin-1 expression in canine mammary tumors.
    Zuccari DA; Castro R; Gavioli AF; Mancini UM; Frade CS; Leonel C
    Genet Mol Res; 2012 Jan; 11(1):153-65. PubMed ID: 22370882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Interleukin 35 Immunoexpression in Malignant Canine Mammary Tumors: Association With Clinicopathological Parameters and Prognosis.
    Carvalho MI; Pires I; Prada J; Pinto C; Gregório H; Cogliati B; Queiroga FL
    Anticancer Res; 2019 Apr; 39(4):2077-2083. PubMed ID: 30952752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.